IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

NCT05359445 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Cancer
Recurrent Cancer
Solid Tumor, Adult
Cancer

Interventions

BIOLOGICAL: IMA401 (Phase Ia)
BIOLOGICAL: Pembrolizumab (Phase Ia)
BIOLOGICAL: IMA 401 (Phase Ib)

Sponsor

Immatics Biotechnologies GmbH